Karyopharm Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Karyopharm Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Karyopharm Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Karyopharm Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Karyopharm Therapeutics Inc (Karyopharm) is a pharmaceutical company focused on the discovery, development, and commercialization of medicines aimed at treating cancer and other serious diseases. The company's main activities involve leveraging the inhibition of nuclear export as a mechanism to develop novel drugs. Its lead product, Xpovio (selinexor), is an oral exportin 1 (XPO1) inhibitor approved for multiple oncology indications and is marketed under the brand name NEXPOVIO in Europe and the UK. Karyopharm's products are used to treat patients with various types of cancer, including multiple myeloma and diffuse large B-cell lymphoma. Its pipeline drug candidates include selinexor, eltanexor, and KPT-9274. Karyopharm’s drug candidates are indicated for the treatment of various hematological and solid tumor malignancies, including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, glioblastoma, and endometrial cancer. The company collaborates with partners for the distribution and commercialization of its products outside the US. It has operations in the US, Israel, and Germany. Karyopharm is headquartered in Newton, Massachusetts, the US
Headquarters
United States of America
Address
85 Wells Avenue, Suite 210, Newton, Massachusetts, 02459
Website
www.karyopharm.com
Telephone
1 617 6580600
No of Employees
228
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KPTI (NASD)
Revenue (2024)
$146.1M
0.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-156.5%
(2024 vs 2023)
Market Cap*
$162.7M
Net Profit Margin (2024)
XYZ
-155.1%
(2024 vs 2023)
* As of and is in US$
Karyopharm Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Selinexor: Oral XPO1 Inhibitor: To treat Multiple Myeloma and DLBCL | Xpovio |
| Pipeline | Nexpovio |
| Selinexor: Myelofibrosis, Endometrial Cancer, Multiple Myeloma, and DLBCL (R/R) | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Karyopharm Therapeutics Inc | Amgen Inc | Incyte Corp | Shanghai Junshi Biosciences Co Ltd | Kite Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | China | United States of America |
| City | Newton | Thousand Oaks | Wilmington | Shanghai | Santa Monica |
| State/Province | Massachusetts | California | Delaware | Shanghai | California |
| No. of Employees | 228 | 31,500 | 2,844 | 2,903 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard Paulson | Director; Chief Executive Officer; President | Executive Board | 2021 | 58 |
| Lori Macomber | Executive Vice President; Treasurer; Chief Financial Officer | Senior Management | 2025 | 55 |
| Kristin Abate | Vice President; Chief Accounting Officer | Senior Management | 2024 | - |
| Michael Mano | Chief Legal Officer; Secretary; Executive Vice President | Senior Management | 2026 | 49 |
| James Accumanno | Chief Compliance Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer